Senior Scientist I, Process Development (AAV)

Role Summary The Senior Scientist I supports development, optimization, and scale-up of AAV manufacturing processes using Sf9/baculovirus and HEK-based systems. This role contributes to early and late-stage CMC activities including process characterization, technology transfer, control strategy development, and regulatory documentation. The level of responsibility, technical leadership, and cross-functional ownership will be commensurate with experience.

Primary Responsibilities • Design, execute, and lead process development and optimization studies for AAV manufacturing using Sf9 cells/baculovirus and HEK platforms.

• Perform hands-on laboratory work to execute process development and optimization experiments, generate critical process data, and support technical troubleshooting.

• Support and, as appropriate, define study designs to drive process optimization, scalability, robustness, and technology transfer for clinical and late-stage programs.

• Collaborate with and provide technical leadership across upstream, downstream, analytical, manufacturing, and quality teams to evaluate process performance and product quality.

• Support or own late-stage CMC deliverables, including process characterization, risk assessments, control strategy development, technology transfer, and validation readiness.

• Author, review, and provide technical input for study protocols, technical reports, and regulatory documentation.

• Support or lead troubleshooting, investigations, mentoring of junior staff, and continuous process improvement initiatives.

Required Skills and Qualifications • Master’s degree in biochemical engineering, bioprocess engineering, molecular biology, cell biology, or relevant life sciences or engineering discipline with a minimum of 6 years of relevant experience, or PhD with at least 3 years of relevant experience.

• Hands-on experience with upstream AAV production using Sf9 cells/baculovirus and HEK platforms required.

• Understanding of virus/viral vector properties and experience with development of upstream and downstream processes for viral vectors or gene therapy products are highly desirable.

• Working knowledge of downstream processing and analytical testing preferred.

• Experience supporting process optimization, characterization, and late-stage CMC activities preferred.

• Demonstrated leadership in process development, cross-functional collaboration, and late-stage CMC readiness is expected.

• Experience authoring and reviewing regulatory documentation preferred.

About LEXEO Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need. Our work culture is a hybrid model with 2 days in the New York City office and 3 days working from home. LEXEO Therapeutics is an EEO employer committed to an exciting, diverse, and enriching work environment.